Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia
NCT07547384Not yet recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of aripiprazole in schizophrenia (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoints: Steady-state Maximum Plasma Concentration and Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady State. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07547384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07547384.